White Coat Hypertension

06/01/1996 - "CONCLUSION:It seems important to evaluate the efficacy of a given antihypertensive drug by analysing patients with white-coat hypertension separately from responders to the medication. "
11/01/1994 - "At present, because of the unpredictability and unreliability of this effect, we recommend that patients with white-coat hypertension should not be included in trials on the efficacy of antihypertensive drugs."
12/06/2022 - "However, this recommendation is based on the study that antihypertensive drug was initiated in mainly "after donor registration" and this may be white-coat hypertension because of donation-related anxiety. "
11/01/2012 - "These data, together with the results of some trials, show the need for the more extensive use of ABPM to identify subjects with white-coat hypertension and to better control the circadian blood pressure profile by administering antihypertensive drugs also in the evening."
09/01/1994 - "It also has a role in the design of antihypertensive trials by ensuring that those with white-coat hypertension are excluded and by reducing the number of subjects necessary for recruitment. "

12/01/2015 - "A growing body of evidence supports the benefits of patient HBPM compared with office-based monitoring: these include improved control of BP, diagnosis of white-coat hypertension and prediction of cardiovascular risk. "
08/01/2012 - "This qualitative study was performed with 71 hypertensive patients, with the objectives to compare outpatient and home blood pressure monitoring (HBPM), to assess blood pressure control, and characterize white-coat hypertension. "
01/01/2013 - "Of the PCPs, 90% routinely used HBPM for white-coat hypertension, treatment titration, and diagnosis. "
12/01/2012 - "The term 'white coat' hypertension (WC-HTN) is intended to reflect the situation in which measurement of blood pressure (BP) by a health professional (often a physician in a white coat) in an office setting is found to be elevated in comparison with BP measured by a more consistent and less error-prone method such as ambulatory BP monitoring (ABPM), or home BP monitoring (HBPM). "
06/01/2009 - "In particular, HBPM often allows to detect white coat hypertension (to be confirmed by 24-hour ambulatory blood pressure measurement). "

11/20/2021 - "The 2017 American College of Cardiology/American Heart Association blood pressure (BP) guideline recommends ambulatory BP monitoring to exclude white coat hypertension (WCH) among adults with office systolic BP (SBP)/diastolic BP (DBP) of 130-159/80-99 mm Hg, and masked hypertension (MHT) among adults with office SBP/DBP of 120-129/75-79 mm Hg after a 3-month trial of lifestyle modification. "
10/01/2019 - "The aim of this study was to determine whether masked hypertension (MHT) and white coat hypertension (WCHT) could be related to increased arterial stiffness and to identify the best office cutoff values of office BP for the diagnosis of MHT and WCHT. "
10/01/2014 - "As demonstrated by studies using population and hypertensive patients, white-coat hypertension (WCHT) and masked hypertension (MHT) carry a particular degree of risk. "
12/01/2019 - "Patients with ambulatory hypertension (AHT), white-coat hypertension (WCHT), MHT, or normotension (NT) were determined. "
09/01/2019 - "The other potential advantage of out-of-clinic BP measurement is the detection of both white-coat hypertension (WCHT) and masked hypertension (MHT). "

06/01/2002 - "These data, which are clinically significant, suggest that 12 weeks of exercise training can result in successful reduction of BP and favorable changes in the lipid profile that would be beneficial to patients with white coat hypertension."
06/01/2002 - "Beneficial effects on blood pressure and lipid profile of programmed exercise training in subjects with white coat hypertension."
11/01/1995 - "White-coat hypertension is not benign and is associated with increased left ventricular mass and altered lipid and endocrine profiles. "
11/01/1995 - "Target organ status and serum lipids in patients with white coat hypertension."
03/01/1996 - "White coat hypertension appears to be a low-risk condition because it is associated with little or no organ damage, and is not usually associated with the metabolic abnormalities characteristic of sustained hypertension, such as high plasma lipid levels. "

09/01/2014 - "Some but not all the relevant studies suggested that white-coat hypertension is associated with subclinical target-organ damage, yet the cross-sectional design of these studies and the fact that these indices are only surrogate end points do not allow firm conclusions to be drawn. "
08/31/2023 - "White-coat hypertension in pregnant women: risk factors, pregnancy outcomes, and biomarkers."
04/01/2008 - "1. This review examines the current evidence for altered mechanical and circulating biomarkers in isolated clinic hypertension and their potential significance. "
04/01/2008 - "Mechanical and circulating biomarkers in isolated clinic hypertension."
12/01/2016 - "The aim of the present study was to investigate the association of circulating miRNAs with white-coat hypertension (WCH) and further analyze whether miRNAs could be as potential biomarkers for WCH. "

03/01/2015 - "Effectiveness of olmesartan-based treatment on home and clinic blood pressure in elderly patients with masked and white coat hypertension."
12/01/2013 - "After 16-week olmesartan-based treatment, the proportion of patients with masked and white coat hypertension changed from 11.8 to 24.2% and 5.6 to 11.9%. "
06/01/2014 - "The authors examined the effects of olmesartan-based treatment on clinic systolic blood pressure (CSBP) and morning home systolic blood pressure (HSBP) in 21,340 patients with masked hypertension (MH), white-coat hypertension (WCH), poorly controlled hypertension (PCH), and well-controlled hypertension (CH) using data from the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure (HONEST) study. "
05/01/2013 - "To better define the prevalence of white coat hypertension (WCH) among patients with type 2 diabetes mellitus and to estimate the magnitude of white coat effect (WCE), before and after antihypertensive therapy, we gathered data from an open-label forced-titration study of a combination of antihypertensive drugs that was titrated sequentially, in the order amlodipine, olmesartan, and hydrochlorothiazide, over an 18-week period among 187 patients with type 2 diabetes mellitus. "

03/01/2013 - "These changes may be indicative or may mediate the differences in cardiovascular mortality in persons with masked and white-coat hypertension, and relevant information about this can be easily accessed with retinal photography."
03/01/2013 - "Divergent retinal vascular abnormalities in normotensive persons and patients with never-treated, masked, white coat hypertension."
03/01/2013 - "We conducted a study in which nonmydriatic retinal photography was used to assess central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) diameters and the retinal arteriovenus ratio (AVR) in a group of 103 individuals with never-treated hypertension of recent (< 1 year) appearance, 28 individuals with masked and 20 with white-coat hypertension, and 50 normotensive individuals, as appropriately classified by ABPM. "
01/01/2016 - "In conclusion, the paradigm that retinal arteriolar narrowing precedes hypertension can be explained by the limitations of CBP measurement, including nonidentification of masked and white-coat hypertension."
03/01/2013 - "Subtle retinal microvascular signs of pathology are observed in hypertensive patients at early stages of hypertension and in patients with both masked and white coat hypertension. "

10/01/2012 - "C-reactive protein and nitric oxide level in patients with white coat hypertension."
11/01/2002 - "The aim of this study was to assess endothelial function, by evaluating circulating nitric oxide metabolites, nitrate plus nitrite (NOx), and endothelium-dependent vasodilation (EDD), in white coat hypertension in comparison with sustained hypertension and normotension. "
11/01/2004 - "The aim of this study was to compare the risk conferred by white coat hypertension (WCH) vs sustained hypertension in the development of the endothelial dysfunction and abnormal angiogenesis by evaluating nitric oxide (NO=NO2+NO3), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and E-selectin levels in plasma. "

09/01/2004 - "One hundred sixty-four elderly patients (age range, 60-80 years; 85 men, 79 women) were included in the study (79 valsartan, 85 amlodipine), and valsartan and amlodipine were reported to have comparable effects on the level and rhythm of 24-hour BP In the present study, 22 of 164 patients had white-coat hypertension at baseline (clinic SBP > or =160 mm Hg and mean 24-hour SBP <130 mm Hg). "
05/01/2013 - "To better define the prevalence of white coat hypertension (WCH) among patients with type 2 diabetes mellitus and to estimate the magnitude of white coat effect (WCE), before and after antihypertensive therapy, we gathered data from an open-label forced-titration study of a combination of antihypertensive drugs that was titrated sequentially, in the order amlodipine, olmesartan, and hydrochlorothiazide, over an 18-week period among 187 patients with type 2 diabetes mellitus. "

05/22/2000 - "Compared with the normotensive subjects, subjects with either persistent or white-coat hypertension had greater mean body mass index, waist-hip ratio, and fasting insulin concentration. "
03/01/1991 - "The relationship between blood pressure and microalbuminuria, both associated with cardiovascular disease and death, is sparsely studied in Type 2 (non-insulin-dependent) diabetes, and results may be interfered by the phenomenon of "white-coat-hypertension". "
06/10/1993 - "White coat hypertension is associated with overweight, lipid abnormalities and high fasting insulin. "
12/01/1991 - "Subjects with white-coat hypertension in Tecumseh appear to be at an increased risk for coronary heart disease: they show repeated elevated clinic readings throughout their life time, their parents have higher blood pressure, their high-density lipoprotein is decreased and insulin, cholesterol and triglycerides are elevated. "
06/06/1994 - "Furthermore, the Tecumseh Blood Pressure Study indicated that not only patients with "sustained" hypertension but also those with so-called "white-coat" hypertension are, as a group, overweight and have elevated levels of cholesterol, insulin, and triglycerides and decreased levels of high-density lipoprotein. "

09/01/2008 - "Trials are now needed to evaluate the risk reduction achievable in patients who have white coat hypertension and are receiving BP-lowering therapy."
10/01/2005 - "A greater proportion of African Americans than Caucasians without white coat hypertension also needed combination therapy (52.1% vs. 39.5%; p=0.04). "
01/01/2002 - "In some difficult cases ('white coat hypertension', 'pseudoresistance to therapy') BPSM should apparently precede 24-hour BP monitoring."
11/16/1990 - "Mostly patients with white coat hypertension who don't need therapy are identified. "
10/01/2014 - "When secondary forms of hypertension and pseudo-resistance, such as medication nonadherence, or white-coat hypertension based on marked differences between clinic and 24-hour ambulatory blood pressure monitoring, have been excluded, the impact of device therapy is under evaluation through clinical trials in the US and from clinical practice registries in Europe and Australia. "

01/01/2023 - "The aim of this meta-analysis is to estimate the prevalence of both white-coat hypertension (WCH) and masked hypertension, along with the prevalence of left ventricular hypertrophy (LVH), in children and young adults with CKD on dialysis or after kidney transplantation. "
02/01/2011 - "ABPM has been able to detect significant differences in blood pressure in many disease states including chronic renal failure, polycystic kidney disease and post renal transplantation and has helped in identifying both white coat hypertension and masked hypertension. "

12/01/2004 - "Individuals who exhibit increases in BP only in the office setting (white coat hypertension) can now avoid unnecessary drug therapy. "
06/17/2002 - "Sensitivity analysis shows that this result holds across a range of costs of pharmacotherapy and proportion of patients with white coat hypertension. "
05/01/2002 - "As such, white coat hypertension is not associated with an increase of cardiovascular morbidity and mortality and thus does not justify drug therapy. "
05/01/1993 - "It has also been used to exclude patients who have white-coat hypertension from pharmacotherapy. "
01/01/2020 - "More than half of the children labeled as "hypertension" on office blood pressure measurement in the study were diagnosed to have white coat hypertension (WCH), thus emphasizing the role of ABPM for evaluation of WCH before the child is subjected to detailed investigations or started on pharmacotherapy."

02/01/2000 - "Blood pressure biofeedback treatment of white-coat hypertension."
02/01/2000 - "The objective of the study was to compare blood pressure (BP) biofeedback treatment (BF) effects between white-coat hypertension and essential hypertension. "

02/01/2004 - "An algorithm has been proposed for the detection of white coat hypertension among subjects with elevated blood pressure (BP) on at least three clinic visits using home BP monitoring (screening test) and, if this is low, ambulatory BP monitoring (diagnostic test). "
05/01/1993 - "In many patients, a clinic visit provokes an increase in blood pressure such that they may be misclassified as being hypertensive (white coat hypertension). "
10/01/2007 - "In above 2/5 of type 2 diabetic patients with newly detected high blood pressure during clinic visits, "white coat hypertension" was diagnosed."